Recent submissions
Now showing items 1-20 of 1219
-
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
(Elsevier BV, 2024-03-19)Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, ... -
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
(AMER ASSOC CANCER RESEARCH, 2024-03-01)UNLABELLED: The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus ... -
Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
(MDPI, 2024-02-28)Ripretinib, a novel tyrosine kinase inhibitor used in advanced gastrointestinal stromal tumors (GIST) resistant to standard therapies, was assessed in the United Kingdom (UK) within an Expanded Access Program (EAP). A ... -
27-hydroxycholesterol and DNA damage repair: implication in prostate cancer.
(FRONTIERS MEDIA SA, 2023-12-21)INTRODUCTION: We previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in ... -
75P U-PRO-CRM: Designing patient-centred dose-finding trials with patient-reported outcomes
(Elsevier BV, 2024-02-01) -
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
(ELSEVIER, 2024-04-01)BACKGROUND AND OBJECTIVE: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific ... -
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
(WILEY, 2024-06-01)BACKGROUND: Elevated circulating growth differentiation factor (GDF15/MIC-1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration-resistant ... -
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.
(AMER ASSOC CANCER RESEARCH, 2024-06-03)PURPOSE: This exploratory analysis evaluated the tumor samples of the patients treated with doxorubicin (with or without olaratumab) in a negative phase III ANNOUNCE trial to better understand the complexity of advanced ... -
Herding clonal evolution to overcome drug resistance in high-grade serous ovarian cancer
(Institute of Cancer Research (University Of London), 2024-06-04)Ovarian cancer (OC) is one of the most common malignancies responsible for cancer-related deaths in women, and finding new treatment strategies is an area of unmet clinical need. To investigate how the concepts of cancer ... -
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as ... -
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
(Elsevier BV, 2024-03-01)For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an ... -
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
(American Society of Clinical Oncology (ASCO), 2024-03-01)PURPOSE: Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to ... -
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
(ELSEVIER, 2024-03-01)In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the ... -
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently ... -
Exploring mechanisms of response and resistance to immuno-oncology approaches in melanoma
(Institute of Cancer Research (University Of London), 2024-05-21)Background Immuno-oncology strategies have transformed the prognosis of advanced melanoma; in particular, immune checkpoint inhibitors (ICIs) provide durable response in a subset of patients, while tebentafusp (tebe) is ... -
Targeting the inflammatory response in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2024-05-20)Prostate cancer is a leading cause of male cancer mortality. Despite inflammation being implicated in prostate cancer initiation and progression, patient outcomes have been minimally impacted by immunotherapies that have ... -
"Why am I still suffering?": Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy.
(ELSEVIER, 2024-06-01)BACKGROUND: Late effects of cancer treatment, such as neurocognitive deficits and fatigue, can be debilitating. Other than head and neck-specific functional deficits such as impairments in swallowing and speech, little is ... -
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
(AMER ASSOC CANCER RESEARCH, 2024-05-15)PURPOSE: Tuvusertib (M1774) is a potent, selective, orally administered ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. This first-in-human study (NCT04170153) evaluated safety, tolerability, maximum ... -
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
(ELSEVIER, 2024-04-01)BACKGROUND: Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4κ monoclonal antibody against human programmed cell death protein 1 (PD-1). This first-in-human, phase I study assessed the safety and efficacy of ... -
Chronic airflow obstruction attributable to poverty in the multinational Burden of Obstructive Lung Disease (BOLD) study.
(BMJ PUBLISHING GROUP, 2023-09-01)Poverty is strongly associated with all-cause and chronic obstructive pulmonary disease (COPD) mortality. Less is known about the contribution of poverty to spirometrically defined chronic airflow obstruction (CAO)-a key ...